Journal of Hepatology
Volume 49, Issue 6 , Pages 899-907 , December 2008

The non-structural 5A protein of hepatitis C virus exhibits genotypic differences in interferon antagonism

  • Ya-Hui Tsai

      Affiliations

    • Graduate Institute of Microbiology, National Taiwan University College of Medicine, Taipei 100, Taiwan
    • ,
  • Wan-Fen Kuang

      Affiliations

    • Hepatitis Research Center, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei 100, Taiwan
    • ,
  • Tsai-Yi Lu

      Affiliations

    • Graduate Institute of Microbiology, National Taiwan University College of Medicine, Taipei 100, Taiwan
    • ,
  • Jia-Horng Kao

      Affiliations

    • Hepatitis Research Center, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei 100, Taiwan
    • ,
  • Ming-Yang Lai

      Affiliations

    • Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei 100, Taiwan
    • ,
  • Chun-Jen Liu

      Affiliations

    • Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei 100, Taiwan
    • ,
  • Pei-Jer Chen

      Affiliations

    • Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei 100, Taiwan
    • ,
  • Lih-Hwa Hwang

      Affiliations

    • Graduate Institute of Microbiology, National Taiwan University College of Medicine, Taipei 100, Taiwan
    • Hepatitis Research Center, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei 100, Taiwan
    • Corresponding Author InformationCorresponding author. Tel.: +886 2 28267114; fax: +886 2 28212880.

Received 9 January 2008 ,Revised 13 May 2008 ,Accepted 26 June 2008.

References 

  1. Di Bisceglie AM, Hoofnagle JH. Optimal therapy of hepatitis C. Hepatology. 2002;36:S121–S127
  2. Pawlotsky JM. Mechanisms of antiviral treatment efficacy and failure in chronic hepatitis C. Antiviral Res. 2003;59:1–11
  3. Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet. 2003;362:2095–2100
  4. Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev. 2001;14:778–809
  5. Katze MG, He Y, Gale M. Viruses and interferon: a fight for supremacy. Nat Rev Immunol. 2002;2:675–687
  6. Mbow ML, Sarisky RT. What is disrupting IFN-alpha’s antiviral activity?. Trends Biotechnol. 2004;22:395–399
  7. Gale M, Foy EM. Evasion of intracellular host defence by hepatitis C virus. Nature. 2005;436:939–945
  8. Thimme R, Lohmann V, Weber F. A target on the move: innate and adaptive immune escape strategies of hepatitis C virus. Antiviral Res. 2006;69:129–141
  9. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest. 1995;96:224–230
  10. Gale M, Blakely CM, Kwieciszewski B, Tan SL, Dossett M, Tang NM, et al. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol Cell Biol. 1998;18:5208–5218
  11. Gale MJ, Korth MJ, Tang NM, Tan SL, Hopkins DA, Dever TE, et al. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology. 1997;230:217–227
  12. Polyak SJ, Paschal DM, McArdle S, Gale MJ, Moradpour D, Gretch DR. Characterization of the effects of hepatitis C virus nonstructural 5A protein expression in human cell lines and on interferon-sensitive virus replication. Hepatology. 1999;29:1262–1271
  13. Podevin P, Sabile A, Gajardo R, Delhem N, Abadie A, Lozach PY, et al. Expression of hepatitis C virus NS5A natural mutants in a hepatocytic cell line inhibits the antiviral effect of interferon in a PKR-independent manner. Hepatology. 2001;33:1503–1511
  14. Francois C, Duverlie G, Rebouillat D, Khorsi H, Castelain S, Blum HE, et al. Expression of hepatitis C virus proteins interferes with the antiviral action of interferon independently of PKR-mediated control of protein synthesis. J Virol. 2000;74:5587–5596
  15. Hallum JV, Thacore HR, Youngner JS. Factors affecting the sensitivity of different viruses to interferon. J Virol. 1970;6:156–162
  16. Stewart WE, Scott WD, Sulkin SE. Relative sensitivities of viruses to different species of interferon. J Virol. 1969;4:147–153
  17. Cheney IW, Lai VC, Zhong W, Brodhag T, Dempsey S, Lim C, et al. Comparative analysis of anti-hepatitis C virus activity and gene expression mediated by alpha, beta, and gamma interferons. J Virol. 2002;76:11148–11154
  18. Guo JT, Zhu Q, Seeger C. Cytopathic and noncytopathic interferon responses in cells expressing hepatitis C virus subgenomic replicons. J Virol. 2003;77:10769–10779
  19. Makarova O, Kamberov E, Margolis B. Generation of deletion and point mutations with one primer in a single cloning step. Biotechniques. 2000;29:970–972
  20. Macdonald A, Harris M. Hepatitis C virus NS5A: tales of a promiscuous protein. J Gen Virol. 2004;85:2485–2502
  21. Reyes GR. The nonstructural NS5A protein of hepatitis C virus: an expanding, multifunctional role in enhancing hepatitis C virus pathogenesis. J Biomed Sci. 2002;9:187–197
  22. Inchauspe G, Zebedee S, Lee DH, Sugitani M, Nasoff M, Prince AM. Genomic structure of the human prototype strain H of hepatitis C virus: comparison with American and Japanese isolates. Proc Natl Acad Sci USA. 1991;88:10292–10296
  23. Duverlie G, Khorsi H, Castelain S, Jaillon O, Izopet J, Lunel F, et al. Sequence analysis of the NS5A protein of European hepatitis C virus 1b isolates and relation to interferon sensitivity. J Gen Virol. 1998;79:1373–1381
  24. Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature. 2005;436:967–972
  25. Neumann AU, Lam NP, Dahari H, Davidian M, Wiley TE, Mika BP, et al. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis. 2000;182:28–35

☆ The authors who have taken part in the research of this paper declared that they do not have a relationship with the manufacturers of the materials involved either in the past or present and they did not receive funding from the manufacturers to carry out their research.

PII: S0168-8278(08)00560-6

doi: 10.1016/j.jhep.2008.06.030

Journal of Hepatology
Volume 49, Issue 6 , Pages 899-907 , December 2008

Article Tools

* Image Usage & Resolution